Altimmune begins MOMENTUM obesity trial for PemvidutideAltimmune has enrolled the first subject in the 48-week Phase 2 MOMENTUM trial evaluating the safety and efficacy of pemvidutide in...
LSG and RYGB-induced upregulation of apoA-IV is beneficial for insulin secretion and energy expenditure19 hours ago
Tirzepatide reduced sleep apnoea severity by up to nearly two-thirds in adults living with OSA and obesity19 hours ago